103 related articles for article (PubMed ID: 3698889)
1. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
[TBL] [Abstract][Full Text] [Related]
2. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
Altamura AC; Buccio M; Colacurcio F; Colombo G; Terzi A
Acta Neurol (Napoli); 1986 Feb; 8(1):19-26. PubMed ID: 3962752
[No Abstract] [Full Text] [Related]
3. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
[TBL] [Abstract][Full Text] [Related]
4. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
Altamura AC; Mauri MC; De Novellis F; Percudani M; Vampini V
Pharmacopsychiatry; 1989 Nov; 22(6):246-9. PubMed ID: 2616635
[TBL] [Abstract][Full Text] [Related]
5. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
[TBL] [Abstract][Full Text] [Related]
6. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients.
Mori K; Yamashita H; Nagao M; Horiguchi J; Yamawaki S
Pharmacopsychiatry; 2002 Jan; 35(1):6-11. PubMed ID: 11819152
[TBL] [Abstract][Full Text] [Related]
7. [A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin].
Gu SF
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Dec; 25(6):328-30, 382. PubMed ID: 1304992
[TBL] [Abstract][Full Text] [Related]
8. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
9. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
Viala A; Aymard N; Leyris A; Caroli F
Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
11. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
12. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
McEvoy JP; Stiller RL; Farr R
J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
[TBL] [Abstract][Full Text] [Related]
13. Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
Meszaros K; Lenzinger E; Hornik K; Schönbeck G; Hatzinger R; Langer G; Sieghart W; Aschauer HN
Neuropsychobiology; 1997; 36(2):69-72. PubMed ID: 9267855
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of acute schizophrenic attacks. High dosage haloperidol therapy compared with a two component treatment].
Blaha L; Zenglein R; Wiedmayer J
Fortschr Med; 1979 Jun; 97(23):1095-1100. PubMed ID: 456997
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of nefazodone in the treatment of neuroleptic induced extrapyramidal side effects: a double-blind randomised parallel group placebo-controlled trial.
Wynchank D; Berk M
Hum Psychopharmacol; 2003 Jun; 18(4):271-5. PubMed ID: 12766931
[TBL] [Abstract][Full Text] [Related]
17. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Timdahl K; Carlsson A; Stening G
Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
[TBL] [Abstract][Full Text] [Related]
18. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
Akhondzadeh S; Safarcherati A; Amini H
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
[TBL] [Abstract][Full Text] [Related]
19. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
20. Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.
Haase HJ; Kaumeier S; Schwarz H; Gundel A; Linde OK; Maetz H; Scheel R; Stripf A; Stripf L
Pharmakopsychiatr Neuropsychopharmakol; 1978 Mar; 11(2):81-5. PubMed ID: 643910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
